Which of the following is NOT an absolute contraindication for fibrinolytic therapy for acute STEMI?

Fibrinolytic therapy for acute ST-Elevation Myocardial Infarction (STEMI) is a critical intervention aimed at quickly dissolving blood clots that obstruct coronary arteries. Certain conditions pose a significant risk during this therapy, leading to stricter contraindications.

Prior use of anticoagulants, while potentially relevant in the clinical decision-making process regarding the timing and type of fibrinolytic therapy, does not constitute an absolute contraindication. Patients may have received anticoagulants for various reasons, and the timing of their administration, as well as the specific anticoagulant used, influences their eligibility for fibrinolytic therapy. Careful evaluation permits the use of fibrinolytics in certain cases even after anticoagulant treatment, which is why this factor is not classified as an absolute contraindication.

In contrast, having an ischemic stroke within the previous three months, active bleeding, or a history of intracranial hemorrhage are considered critical contraindications. These conditions significantly increase the risk of serious complications, such as major bleeding or hemorrhagic stroke, making fibrinolytic therapy inappropriate for affected patients. Hence, when evaluating a patient for fibrinolytic therapy in the setting of STEMI, understanding these contraindications is essential for